None listed
Conditions
Brief summary
Low uptake of influenza vaccine and pertussis vaccine in pregnancy in New Zealand needs to be addressed. The hypothesis we seek to test is that providing funded pertussis and influenza vaccinations in pregnancy through community pharmacy will increase uptake in pregnant women, including those living in areas of higher household deprivation, and in women of Maori ethnicity. In one area of NZ (intervention area) these vaccinations will be funded through community pharmacies as well as the traditional areas (general practice and hospitals). In geographically comparable areas (controls) funding remains standard (general practice and hospital). The study will measure uptake overall and by location of vaccine delivery in women, and a further analysis will examine uptake in Maori and high deprivation populations,
Interventions
Influenza vaccine was funded in pregnancy in pharmacy nationally, ie in all areas as from 1 April 2017. and Waikato started from Nov 2016 funding pertussis. This will now be called an observational study.
Drugs and dose: Combined diphtheria-tetanus-acellular pertussis vaccine (funded for a single delivery between week 28 and week 38 of pregnancy) and influenza vaccine (funded for a single delivery at any stage of pregnancy), both vaccines will be delivered by intra-muscular injection. The period
Influenza vaccine was funded in pregnancy in pharmacy nationally, ie in all areas as from 1 April 2017. and Waikato started from Nov 2016 funding pertussis. This will now be called an observational study. Drugs and dose: Combined diphtheria-tetanus-acellular pertussis vaccine (funded for a single delivery between week 28 and week 38 of pregnancy) and influenza vaccine (funded for a single delivery at any stage of pregnancy), both vaccines will be delivered by intra-muscular injection. The period observed will be 24 months. Any pregnant woman in the Waikato will be able to present to a pharmacy (or traditional areas ie general practice or hospitals) for the funded vaccinations.
Sponsors
Dr Natalie Gauld
Study design
Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Healthy volunteers
Yes
Inclusion criteria
Women who were pregnant during the observed period, are NZ residents, were eligible for the vaccinations during the study period, and have a surviving fetus beyond 27 weeks. Note: women will not be enrolled as such for the primary outcome, and data will only be used for women who had the vaccinations and had a surviving fetus beyond 27 weeks. Women will be eligible for the vaccinations if pregnant but if they do not have a surviving fetus beyond 27 weeks will not be included. For the secondary qualitative research, women will be invited to participate in an interview and only with informed consent will the interview progress.
Exclusion criteria
Women who deliver before 27 weeks, or who do not deliver a live baby. Women who are not eligible for funded vaccines (e.g. not NZ residents).
Outcome results
None listed